Literature DB >> 1623525

A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction.

G Pelicci1, L Lanfrancone, F Grignani, J McGlade, F Cavallo, G Forni, I Nicoletti, F Grignani, T Pawson, P G Pelicci.   

Abstract

A new SH2-containing sequence, SHC, was isolated by screening cDNA libraries with SH2 representative DNA probes. The SHC cDNA is predicted to encode overlapping proteins of 46.8 and 51.7 kd that contain a single C-terminal SH2 domain, and an adjacent glycine/proline-rich motif with regions of homology with the alpha 1 chain of collagen, but no identifiable catalytic domain. Anti-SHC antibodies recognized three proteins of 46, 52, and 66 kd in a wide range of mammalian cell lines. These SHC proteins complexed with and were phosphorylated by activated epidermal growth factor receptor. The physical association of SHC proteins with activated receptors was recreated in vitro by using a bacterially expressed SHC SH2 domain. NIH 3T3 mouse fibroblasts that constitutively overexpressed SHC acquired a transformed phenotype in culture and formed tumors in nude mice. These results suggest that the SHC gene products couple activated growth factor receptors to a signaling pathway that regulates the proliferation of mammalian cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1623525     DOI: 10.1016/0092-8674(92)90536-l

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  331 in total

1.  The ShcA phosphotyrosine docking protein sensitizes cardiovascular signaling in the mouse embryo.

Authors:  K M Lai; T Pawson
Journal:  Genes Dev       Date:  2000-05-01       Impact factor: 11.361

Review 2.  Protein-protein interaction in insulin signaling and the molecular mechanisms of insulin resistance.

Authors:  A Virkamäki; K Ueki; C R Kahn
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

3.  ShcA tyrosine phosphorylation sites can replace ShcA binding in signalling by middle T-antigen.

Authors:  P R Nicholson; S Empereur; H R Glover; S M Dilworth
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

4.  Regulation of insulin-stimulated tyrosine phosphorylation of Shc and Shc/Grb2 association in liver, muscle, and adipose tissue of epinephrine- and streptozotocin-treated rats.

Authors:  V Páez-Espinosa; E M Rocha; L A Velloso; M J Saad
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

Review 5.  Natural biology of polyomavirus middle T antigen.

Authors:  K A Gottlieb; L P Villarreal
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

6.  Tumor induction by a transformation-defective polyoma virus mutant blocked in signaling through Shc.

Authors:  R Bronson; C Dawe; J Carroll; T Benjamin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

7.  Distinct tyrosine autophosphorylation sites negatively and positively modulate neu-mediated transformation.

Authors:  D L Dankort; Z Wang; V Blackmore; M F Moran; W J Muller
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

8.  Control of thrombopoietin-induced megakaryocytic differentiation by the mitogen-activated protein kinase pathway.

Authors:  M C Rouyez; C Boucheron; S Gisselbrecht; I Dusanter-Fourt; F Porteu
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

9.  Evidence for a requirement for both phospholipid and phosphotyrosine binding via the Shc phosphotyrosine-binding domain in vivo.

Authors:  K S Ravichandran; M M Zhou; J C Pratt; J E Harlan; S F Walk; S W Fesik; S J Burakoff
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

10.  Multiple-state reactions between the epidermal growth factor receptor and Grb2 as observed by using single-molecule analysis.

Authors:  Miki Morimatsu; Hiroaki Takagi; Kosuke G Ota; Ryo Iwamoto; Toshio Yanagida; Yasushi Sako
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.